Divi's Laboratories Limited
DIVISLAB · Pharma · NSE
₹6,268
Current Market Price
Fair Value (DCF)
₹2,520
Margin of Safety
-59.8%
Updated just now
YieldIQ Score
43/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
37%
ROE
14.6%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹1.66 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.9%
Return on capital employed
EV / EBITDA
46.9×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
1459.0×
EBIT covers interest
Current Ratio
6.94×
Short-term liquidity
Asset Turnover
0.58×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹6,268
Bear case
₹1,516.29
MoS -313.4%
Base case
₹2,520.25
MoS -148.7%
Bull case
₹3,427.14
MoS -82.9%
Ratio Trends
DIVISLAB · last 8 annual periods
ROE
14.6%
ROCE
22.2%
Operating Margin
—
Debt / Equity
0.00×
PE
0.8×
EV / EBITDA
—
Historical Financials
DIVISLAB · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹6969 Cr | ₹8960 Cr | ₹1951 Cr | ₹2303 Cr | ₹9325 Cr | +7.6% |
| EBITDA | — | ₹3995 Cr | ₹2712 Cr | ₹2544 Cr | ₹3320 Cr | -4.5% |
| EBIT | ₹2667 Cr | ₹3684 Cr | ₹467 Cr | ₹715 Cr | — | -28.0% |
| PAT | ₹1984 Cr | ₹2960 Cr | ₹321 Cr | ₹538 Cr | ₹2191 Cr | +2.5% |
| EPS (diluted) | ₹74.75 | ₹111.52 | ₹12.09 | ₹20.25 | — | -27.9% |
| CFO | ₹1947 Cr | ₹1912 Cr | ₹2460 Cr | ₹1261 Cr | ₹1653 Cr | -4.0% |
| CapEx | — | — | — | — | ₹-1438 Cr | — |
| FCF | — | — | — | — | ₹215 Cr | +0.0% |
| Total Assets | — | ₹13.4K Cr | ₹14.4K Cr | ₹15.5K Cr | ₹16.9K Cr | +6.1% |
| Total Debt | — | — | ₹0.0 Cr | ₹0.0 Cr | ₹4.0 Cr | — |
| Shareholders' Equity | — | — | ₹12.8K Cr | ₹13.6K Cr | ₹15.0K Cr | +4.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
DIVISLAB vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| TORNTPHARM Torrent Pharmaceuticals Limited | -48.8% | 28 | Overvalued | 25.2% | — |
| LUPIN Lupin Limited | +16.1% | 37 | Undervalued | 19.0% | — |
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| CIPLA Cipla Limited | +43.1% | 66 | Data Limited | 16.9% | 22.1× |
| ZYDUSLIFE Zydus Lifesciences Limited | +47.7% | 45 | Data Limited | 17.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
9 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹140.00/sh
Last payout
2025-07-25
₹30.00
Peak payout
₹30.00
Trailing yield
0.48%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Divi's Laboratories Limited (DIVISLAB.NS) trades at 6268.00 vs a model fair value of 2520.25, a gap of -59.8%. Piotroski F-score: 6/9. Mo...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of DIVISLAB →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for DIVISLAB →
Compare
Head-to-head with peers
Compare DIVISLAB side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse DIVISLABNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.